OLMA
OlemaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
9
U.S. public peers
Grade Position
Below peers
vs peer average
OLMA vs peer average
34/100
OLMA vs. peer average (D vs. C)
Grade spread
A 2 · B 1 · C 3 · D 1 · F 2
Graded peers loaded
Coverage
9 graded
100% of tracked
Peer overview
AZN is the first available peer comparator.
Relevant oral-SERD clinical comparator, not a market-cap peer. SERENA-4 tested first-line camizestrant plus palbociclib, whereas OPERA-01 tests later-line palazestrant monotherapy; its miss is a sentiment read-through, not evidence that OPERA-01 will fail [#PR-AZN-2026-09-11].
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
OLMA
Olema
AZN
AstraZeneca
Grade
D
F
Momentum
4
63
Value
41
62
Sentiment
60
12
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Grade position vs AZN
OLMA / AZN
Grade Position
Below peers
OLMA vs. peer average (D vs. C)
34/100
Momentum
4
AZNValue
41
AZNSentiment
60
OLMARotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs OLMA
AZN is the first peer returned for this comparison set.